Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis

Molecular Therapy

Volumn 22, Issue 8, 2014, Pages 1472-1483

  Chiriaco, Maria ^a   Farinelli, Giada ^b   Capo, Valentina ^a   Zonari, Erika ^b   Scaramuzza, Samantha ^b   Di Matteo, Gigliola ^a   Sergi, Lucia Sergi ^b   Migliavacca, Maddalena ^b   Hernandez, Raisa Jofra ^b   Bombelli, Ferdinando ^c   Giorda, Ezio ^d   Kajaste Rudnitski, Anna ^b   Trono, Didier ^e   Grez, Manuel ^f   Rossi, Paolo ^a   Finocchi, Andrea ^a   Naldini, Luigi ^b,g   Gentner, Bernhard ^b   Aiuti, Alessandro ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e EPFL   (Switzerland)

^f INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA 126; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; CD34 ANTIGEN; CYBB PROTEIN, HUMAN; MEMBRANE PROTEIN; MICRORNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD34 SELECTION; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; FEMALE; GRANULOMATOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MYELOID SPECIFIC PROMOTER; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PROGENY; PROMOTER REGION; PROTEIN EXPRESSION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; X LINKED CHRONIC GRANULOMATOSIS; XENOTRANSPLANTATION; ANIMAL; BONE MARROW CELL; CELL CULTURE; CELL LINE; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL; LENTIVIRINAE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; THERAPEUTIC USE; VIROLOGY;

MUS;

ANIMALS; ANTIGENS, CD34; CELL LINE; CELLS, CULTURED; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; MEMBRANE GLYCOPROTEINS; MICE; MICRORNAS; MYELOID CELLS; NADPH OXIDASE;

EID: 84905451458     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.87     Document Type: Article

References (46)

1. Holland, SM (2010). Chronic granulomatous disease. Clin Rev Allergy Immunol 38: 3-10.
2. Seger, RA (2010). Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 68: 334-340.
3. Di Matteo, G, Giordani, L, Finocchi, A, Ventura, A, Chiriaco, M, Blancato, J et al. ; IPINET (Italian Network for Primary Immunodeficiencies). (2009). Molecular characterization of a large cohort of patients with Chronic Granulomatous Disease and identification of novel CYBB mutations: an Italian multicenter study. Mol Immunol 46: 1935-1941.
4. Roos, D, Kuhns, DB, Maddalena, A, Bustamante, J, Kannengiesser, C, de Boer, M et al. (2010). Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis 44: 291-299.
5. Seger, RA (2008). Modern management of chronic granulomatous disease. Br J Haematol 140: 255-266.
6. Arruda, VR, Favaro, P and Finn, JD (2009). Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther 17: 1492-1503.
7. Martinez, CA, Shah, S, Shearer, WT, Rosenblatt, HM, Paul, ME, Chinen, J et al. (2012). Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol 129: 176-183.
8. Aiuti, A, Bacchetta, R, Seger, R, Villa, A and Cavazzana-Calvo, M (2012). Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol 24: 585-591.
9. Gennery, AR, Slatter, MA, Grandin, L, Taupin, P, Cant, AJ, Veys, P et al. ; Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. (2010). Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 126: 602-10. e1.
10. Güngör, T, Teira, P, Slatter, M, Stussi, G, Stepensky, P, Moshous, D et al. ; Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. (2014). Reduced-intensity conditioning and HLA-matched haemopoietic stemcell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 383: 436-448.
11. Kang, EM, Choi, U, Theobald, N, Linton, G, Long Priel, DA, Kuhns, D et al. (2010). Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115: 783-791.
12. Kang, HJ, Bartholomae, CC, Paruzynski, A, Arens, A, Kim, S, Yu, SS et al. (2011). Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. Mol Ther 19: 2092-2101.
13. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
14. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
15. Wu, C and Dunbar, CE (2011). Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Front Med 5: 356-371.
16. Bedard, K and Krause, KH (2007). The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313.
17. Yahata, T, Takanashi, T, Muguruma, Y, Ibrahim, AA, Matsuzawa, H, Uno, T et al. (2011). Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. Blood 118: 2941-2950.
18. Grez, M, Reichenbach, J, Schwäble, J, Seger, R, Dinauer, MC and Thrasher, AJ (2011). Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 19: 28-35.
19. Naldini, L (2011). Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12: 301-315.
20. Santilli, G, Almarza, E, Brendel, C, Choi, U, Beilin, C, Blundell, MP et al. (2011). Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 19: 122-132.
21. Brendel, C, Hänseler, W, Wohlgensinger, V, Bianchi, M, Tokmak, S, Chen-Wichmann, L et al. (2013). Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy. Hum Gene Ther Methods 24: 151-159.
22. Brendel, C, Müller-Kuller, U, Schultze-Strasser, S, Stein, S, Chen-Wichmann, L, Krattenmacher, A et al. (2012). Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther 19: 1018-1029.
23. Barde, I, Laurenti, E, Verp, S, Wiznerowicz, M, Offner, S, Viornery, A et al. (2011). Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Gene Ther 18: 1087-1097.
24. Brown, BD, Gentner, B, Cantore, A, Colleoni, S, Amendola, M, Zingale, A et al. (2007). Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25: 1457-1467.
25. Brown, BD, Venneri, MA, Zingale, A, Sergi Sergi, L and Naldini, L (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12: 585-591.
26. Gentner, B and Naldini, L (2012). Exploiting microRNA regulation for genetic engineering. Tissue Antigens 80: 393-403.
27. Gentner, B, Visigalli, I, Hiramatsu, H, Lechman, E, Ungari, S, Giustacchini, A et al. (2010). Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci Transl Med 2: 58ra84.
28. He, W, Qiang, M, Ma, W, Valente, AJ, Quinones, MP, Wang, W et al. (2006). Development of a synthetic promoter for macrophage gene therapy. Hum Gene Ther 17: 949-959.
29. Moreno-Carranza, B, Gentsch, M, Stein, S, Schambach, A, Santilli, G, Rudolf, E et al. (2009). Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther 16: 111-118.
30. Berger, G, Durand, S, Goujon, C, Nguyen, XN, Cordeil, S, Darlix, JL et al. (2011). A simple, versatile and efficient method to genetically modify human monocytederived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc 6: 806-816.
31. Hrecka, K, Hao, C, Gierszewska, M, Swanson, SK, Kesik-Brodacka, M, Srivastava, S et al. (2011). Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658-661.
32. Wang, S, Aurora, AB, Johnson, BA, Qi, X, McAnally, J, Hill, JA et al. (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15: 261-271.
33. Lechman, ER, Gentner, B, van Galen, P, Giustacchini, A, Saini, M, Boccalatte, FE et al. (2012). Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell 11: 799-811.
34. Li, Z, Lu, J, Sun, M, Mi, S, Zhang, H, Luo, RT et al. (2008). Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 105: 15535-15540.
35. Harnprasopwat, R, Ha, D, Toyoshima, T, Lodish, H, Tojo, A and Kotani, A (2010). Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126. Biochem Biophys Res Commun 399: 117-122.
36. Zhang, F, Frost, AR, Blundell, MP, Bales, O, Antoniou, MN and Thrasher, AJ (2010). A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 18: 1640-1649.
37. Björgvinsdóttir, H, Ding, C, Pech, N, Gifford, MA, Li, LL and Dinauer, MC (1997). Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 89: 41-48.
38. Scaramuzza, S, Biasco, L, Ripamonti, A, Castiello, MC, Loperfido, M, Draghici, E et al. (2013). Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol Ther 21: 175-184.
39. Kustikova, OS, Schiedlmeier, B, Brugman, MH, Stahlhut, M, Bartels, S, Li, Z et al. (2009). Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 17: 1537-1547.
40. Montini, E and Cesana, D (2012). Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a-/- mice. Methods Enzymol 507: 171-185.
41. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knöss, S, Schambach, A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
42. Biffi, A, Montini, E, Lorioli, L, Cesani, M, Fumagalli, F, Plati, T et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341: 1233158.
43. Aiuti, A, Biasco, L, Scaramuzza, S, Ferrua, F, Cicalese, MP, Baricordi, C et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341: 1233151.
44. Gentner, B, Schira, G, Giustacchini, A, Amendola, M, Brown, BD, Ponzoni, M et al. (2009). Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6: 63-66.
45. Follenzi, A and Naldini, L (2002). HIV-based vectors. Preparation and use. Methods Mol Med 69: 259-274.
46. Mayo, LA and Curnutte, JT (1990). Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells. Methods Enzymol 186: 567-575.